(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 January 2013 (24.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/012747 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *G01N 33/574* (2006.01)

(21) International Application Number:
PCT/US2012/046746

(22) International Filing Date:
13 July 2012 (13.07.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/508,403	15 July 2011 (15.07.2011)	US
61/521,547	9 August 2011 (09.08.2011)	US
61/570,629	14 December 2011 (14.12.2011)	US

(71) Applicant *(for all designated States except US)*: **ONCOMED PHARMACEUTICALS, INC.** [US/US]; 800 Chesapeake Drive, Redwood City, CA 94063 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GURNEY, Austin, L.** [US/US]; 946 Diamond Street, San Francisco, CA 94114 (US). **AXELROD, Fumiko, Takada** [US/US]; 3780 Wright Place, Palo Alto, CA 94306 (US). **HOEY, Timothy, Charles** [US/US]; 200 Darrell Road, Hillsborough, CA 94010 (US). **CHARTIER-COURTAUD, Cecile** [FR/US]; 1357 Cowper Street, Palo Alto, CA 94301 (US).

(74) Agents: **CALVO, Paul, A.** et al.; Sterne, Kessler, Goldstein & Fox, PLLC, 1100 New York Avenue, NW, Washington, DC 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

WO 2013/012747 A1

(54) Title: RSPO BINDING AGENTS AND USES THEREOF

(57) Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.